REG - GSK PLC - Director/PDMR Shareholding
Mon 15:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nRSN9860Qa&default-theme=true
RNS Number : 9860Q GSK PLC 14 July 2025
GSK plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2073 8 (partnership shares)
£14.2073 8 (matching shares)
d) Aggregated information
Aggregated volume Price 16 Ordinary Shares
£14.2073
e) Date of the transaction 2025-07-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Julie Brown
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2073 9 (partnership shares)
£14.2073 9 (matching shares)
d) Aggregated information
Aggregated volume Price 18 Ordinary Shares
£14.2073
e) Date of the transaction 2025-07-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2073 9 (partnership shares)
£14.2073 9 (matching shares)
d) Aggregated information
Aggregated volume Price 18 Ordinary Shares
£14.2073
e) Date of the transaction 2025-07-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2073 9 (partnership shares)
£14.2073 9 (matching shares)
d) Aggregated information
Aggregated volume Price 18 Ordinary Shares
£14.2073
e) Date of the transaction 2025-07-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2073 9 (partnership shares)
£14.2073 9 (matching shares)
d) Aggregated information
Aggregated volume Price 18 Ordinary Shares
£14.2073
e) Date of the transaction 2025-07-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2073 9 (partnership shares)
£14.2073 9 (matching shares)
d) Aggregated information
Aggregated volume Price 18 Ordinary Shares
£14.2073
e) Date of the transaction 2025-07-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Philip Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2073 9 (partnership shares)
£14.2073 9 (matching shares)
d) Aggregated information
Aggregated volume Price 18 Ordinary Shares
£14.2073
e) Date of the transaction 2025-07-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2073 9 (partnership shares)
£14.2073 9 (matching shares)
d) Aggregated information
Aggregated volume Price 18 Ordinary Shares
£14.2073
e) Date of the transaction 2025-07-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.2073 9 (partnership shares)
£14.2073 9 (matching shares)
d) Aggregated information
Aggregated volume Price 18 Ordinary Shares
£14.2073
e) Date of the transaction 2025-07-09
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 32
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 5
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 12
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 21
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 3
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 84
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 32
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Philip Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 54
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 70
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on shares held through the Company's Share
Reward Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.4447 65
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 1,708
£14.5450 1,511
£14.5450 1,158
d) Aggregated information
Aggregated volume Price 4,377
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Julie Brown
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 651
£14.5450 758
d) Aggregated information
Aggregated volume Price 1,409
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 169
£14.5450 275
£14.5450 430
d) Aggregated information
Aggregated volume Price 874
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 267
£14.5450 436
£14.5450 264
d) Aggregated information
Aggregated volume Price 967
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Sally Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 270
£14.5450 148
£14.5450 166
d) Aggregated information
Aggregated volume Price 584
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 811
£14.5450 407
£14.5450 644
d) Aggregated information
Aggregated volume Price 1,862
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends
paid to shareholders on 10 July 2025 on ADSs held in the Company's Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$39.5800 131
$39.5800 123
$39.5800 204
d) Aggregated information
Aggregated volume Price 458
$39.5800
e) Date of the transaction 2025-07-10
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 372
£14.5450 516
£14.5450 235
d) Aggregated information
Aggregated volume Price 1,123
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 345
£14.5450 622
£14.5450 299
d) Aggregated information
Aggregated volume Price 1,266
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Philip Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 195
£14.5450 209
£14.5450 347
d) Aggregated information
Aggregated volume Price 751
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 476
£14.5450 324
£14.5450 538
d) Aggregated information
Aggregated volume Price 1,338
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 10 July 2025 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 662
£14.5450 302
£14.5450 226
d) Aggregated information
Aggregated volume Price 1,190
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Emma Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025 on Ordinary Shares held in the Company's
Performance Share Plan subject to a 2-year holding period
c) Price(s) and volume(s) Price(s) Volume(s)
£14.5450 4,680.094
£14.5450 5,119.467
d) Aggregated information N/A (single transaction)
Aggregated volume Price
9,799.561
£14.5450
e) Date of the transaction 2025-07-10
f) Place of the transaction London Stock Exchange (XLON)
d)
Aggregated information
Aggregated volume Price
N/A (single transaction)
9,799.561
£14.5450
e)
Date of the transaction
2025-07-10
f)
Place of the transaction
London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Elizabeth McKee Anderson
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 July 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$38.5396 27
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-11
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Charles Bancroft
b) Position/status Senior Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 July 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$38.5396 364
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-11
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Hal Barron
b) Position/status Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 July 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$38.5396 30
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-11
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Anne Beal
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 July 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$38.5396 35
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-11
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Harry Dietz
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 July 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$38.5396 34
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-11
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Jeannie Lee
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 July 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$38.5396 11
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-11
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr Vishal Sikka
b) Position/status Independent Non-Executive Director
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W2044
b) Nature of the transaction Acquisition of ADSs following the re-investment of dividends paid to
shareholders on 10 July 2025
c) Price(s) and volume(s) Price(s) Volume(s)
$38.5396 103
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-11
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025, on Ordinary Shares held within an ISA
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3784 23
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-11
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 10 July 2025, on Ordinary Shares held within an ISA
c) Price(s) and volume(s) Price(s) Volume(s)
£14.3784 19
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2025-07-11
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFAFLLEISESWRecent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Transaction in Own Shares
Announcement